摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-2-(2-methoxy-2-oxoethyl)-4-methylpentanoic acid | 162678-79-7

中文名称
——
中文别名
——
英文名称
(R)-2-(2-methoxy-2-oxoethyl)-4-methylpentanoic acid
英文别名
(2R)-2-isobutyl-3-(methoxycarbonyl)propanoic acid;(2R)-2-[(methoxycarbonyl)methyl]-4-methylpentanoic acid;(2R)-2-(2-methoxy-2-oxoethyl)-4-methylpentanoic acid
(R)-2-(2-methoxy-2-oxoethyl)-4-methylpentanoic acid化学式
CAS
162678-79-7
化学式
C9H16O4
mdl
——
分子量
188.224
InChiKey
REUDDXCWANRXHG-SSDOTTSWSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    288.6±23.0 °C(Predicted)
  • 密度:
    1.069±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    13
  • 可旋转键数:
    6
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.78
  • 拓扑面积:
    63.6
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    Matrix Metalloproteinase Inhibitors:  A Structure−Activity Study
    摘要:
    Modifications around the dipeptide-mimetic core of a hydroxamic acid based matrix metalloproteinase inhibitor were studied. These variations incorporated a variety of natural, unnatural, and synthetic amino acids in addition to modifications of the P1' and P3' substituents. The results of this study indicate the following structural requirements: (1) Two key hydrogen bonds must be present between the enzyme and potent substrates. (2) Potent inhibitors must possess strong zinc-binding functionalities. (3) The potential importance of the hydrophobic group at position R3 as illustrated by its ability to impart greater relative potency against stromelysin when larger hydrophobic groups are used. (4) Requirements surrounding the nature of the amino acid appear to be more restrictive for stromelysin than for neutrophil collagenase, 72 kDa gelatinase, and 92 kDa gelatinase. These requirements may involve planar fused-ring aryl systems and possibly hydrogen-bonding capabilities.
    DOI:
    10.1021/jm970494j
  • 作为产物:
    描述:
    参考文献:
    名称:
    Matrix Metalloproteinase Inhibitors:  A Structure−Activity Study
    摘要:
    Modifications around the dipeptide-mimetic core of a hydroxamic acid based matrix metalloproteinase inhibitor were studied. These variations incorporated a variety of natural, unnatural, and synthetic amino acids in addition to modifications of the P1' and P3' substituents. The results of this study indicate the following structural requirements: (1) Two key hydrogen bonds must be present between the enzyme and potent substrates. (2) Potent inhibitors must possess strong zinc-binding functionalities. (3) The potential importance of the hydrophobic group at position R3 as illustrated by its ability to impart greater relative potency against stromelysin when larger hydrophobic groups are used. (4) Requirements surrounding the nature of the amino acid appear to be more restrictive for stromelysin than for neutrophil collagenase, 72 kDa gelatinase, and 92 kDa gelatinase. These requirements may involve planar fused-ring aryl systems and possibly hydrogen-bonding capabilities.
    DOI:
    10.1021/jm970494j
点击查看最新优质反应信息

文献信息

  • Novel method of treatment of inflammatory skin conditions
    申请人:Chandler Rupert Stephen
    公开号:US20070049518A1
    公开(公告)日:2007-03-01
    There is provided, inter alia, a method for the treatment or prevention of an inflammatory skin condition which is characterised by colonisation with Staphylococcus aureus , comprising the topical administration of an aureolysin inhibitor.
    提供了一种治疗或预防由金黄色葡萄球菌定植引起的炎症性皮肤病的方法,包括局部施用一种金黄色葡萄球菌溶素抑制剂。
  • Inhibitors of anthrax lethal factor
    申请人:Rideout Darryl
    公开号:US20070197577A1
    公开(公告)日:2007-08-23
    Methods, compounds and compositions for preventing and treating anthrax infections by inhibiting Anthrax Lethal Factor (LF) activity.
    通过抑制炭疽病致命因子(LF)活性,预防和治疗炭疽感染的方法,化合物和组合物。
  • WO2007/25999
    申请人:——
    公开号:——
    公开(公告)日:——
  • [EN] INHIBITORS OF ANTHRAX LETHAL FACTOR<br/>[FR] INHIBITEURS DU FACTEUR LETAL DU CHARBON
    申请人:CENGENT THERAPEUTICS
    公开号:WO2005027856A3
    公开(公告)日:2006-10-12
  • EP0690841A4
    申请人:——
    公开号:EP0690841A4
    公开(公告)日:1996-03-13
查看更多